Management of early stage Hodgkin's disease: The role of radiation therapy and/or chemotherapy

Annals of Oncology

Volumn 7, Issue SUPPL. 4, 1996, Pages

  Mauch, P M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JCRT   (United States)

Author keywords

Early stages; Hodgkin's disease; Prognostic factors; Radiation therapy; Splenectomy

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; EPIRUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; EARLY CANCER; HODGKIN DISEASE; HUMAN; LAPAROTOMY; PRIORITY JOURNAL; PROGNOSIS; RADIATION FIELD; SPLENECTOMY;

EID: 0029797388     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/7.suppl_4.S79     Document Type: Conference Paper

References (24)

1. Anderson H, Crowther D, Deakin D et al. A randomized study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-Year follow-up. Ann Oncol 1991;2:49.
2. Aragon de la Cruz G, Cardenes H, Otero J et al. Individual risk of abdominal disease in patients with stages I and II supradiaphragmatic Hodgkin's disease. Cancer 1989;63:1799-803.
3. Biti G, Cimino G, Cartoni C et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized study. J Clin Oncol 1992; 10: 378-82.
4. Blokhina N, Aliev B, Kruglova G et al. The treatment of patients with lymphogranulomatosis, clinical stages I and II. Vestn AMN SSSR 1985;1:45-9.
5. Bloomfield C, Pajak T, Glicksman A et al. Chemotherapy and combined modality therapy for Hodgkin's disease: A progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep 1982;66:835-46.
6. Brada M, Easton D, Horwich A et al. Clinical presentation as a predictor of laparotomy findings in supradiaphragmatic stage I and II Hodgkin's disease. Radiother Oncol 1986;5:15-22.
7. Cadman E, Bloom A, Prosnitz L et al. The effective use of combined modality therapy for the treatment of patients with Hodgkin's disease who relapsed following radiotherapy. Am J Clin Oncol 1983;6:313-8.
8. Carde P, Burgers J, Henry-Amar M et al. Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors. J Clin Oncol 1988;6:239-52.
9. Cosset J, Henry-Amar M, Meerwaldt J. Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience. Ann Oncol 1991;2:77-82.
10. Cmkovich M, Leopold K, Hoppe R, Mauch P. Stage I to IIB Hodgkin's disease: The combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 1987;5:1041-9.
11. Diehl V, Pfreundschuh M, Loffler M et al. Therapiestudien der deutschen Hodgkin-Studiengruppe. Zwischenergebnisse der Studienprotokolle HD1, HD2 and HD3. Onkologie 1987; 10: 62-6.
12. Dutcher J, Wiernik P. Combined modality treatment of Hodgkin's disease comfined to lymph nodes. Dev Oncology 1985;32:317-27.
13. Easson E, Russell M. The cure of Hodgkin's disease. Br Med J 1963;1:1704-7.
14. Farah J, Ultmann J, Griem M et al. Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease. J Clin Oncol 1988;6:1047-52.
15. Fuller L, Hutchison G. Collaborative clinical trial for stage I and II Hodgkin's disease: Significance of mediastinal and non-mediastinal disease in laparotomy- and non-laparotomy-staged patients. Cancer Treat Rep 1982;66:775-87.
16. Fuller L, Madoc-Jones H, Shullenberger C et al. Further follow-up of results of treatment in 90 laparotomy-negative stage I and II Hodgkin's disease patients: Significance of mediastinal and non-mediastinal presentations. Int J Radiat Oncol Biol Phys 1980;6:799-808.
17. Ganesan T, Wrigley P, Murray P et al. Radiotherapy for stage I Hodgkin's disease: 20 Years of experience at St Bartholomew's Hospital. Br J Cancer 1990;62:314-8.
18. Gilbert R. La roentgentherapie de la granulomatose maligne. J Radiol Electrol 1925;9:509-14.
19. Gospodarowicz M, Sutcliffe S, Clark R et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int J Radiat Onc Biol Phys 1992;22:859-65.
20. Hancock S, Hoppe R, Horning S, Rosenberg S. Intercurrent death after Hodgkin's disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med 1988;109:183-9.
21. Haybittle J, Easterling M, Bennett M et al. Review of British national lymphoma investigation studies of Hodgkin's disease and development of prognostic index. The Lancet 1985; 1: 967-72.
22. Healey E, Tarbell N, Kalish L et al. Prognostic factors for patients with Hodgkin's disease in first relapse. Cancer 1993; 71:2613-20.
23. Henry-Amar M. Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin's disease. J Natl Cancer Inst 1983;71:911-6.
24. Henry-Amar M, Hayat M, Meerwaldt J et al. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. Int J Radiat Oncol Biol Phys 1990; 19: 1155-7.